N/A
Manufactured by Aurobindo Pharma Limited
24 FDA adverse event reports analyzed
Last updated: 2026-05-19
Trelegy is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for Trelegy include DEATH, HOSPICE CARE, HOSPITALISATION, ACNE, ASTHENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for Trelegy.
Out of 18 classified reports for Trelegy:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 24 FDA FAERS reports that mention Trelegy. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, HOSPICE CARE, HOSPITALISATION, ACNE, ASTHENIA, ASTHMA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with Trelegy. Always verify the specific product and NDC with your pharmacist.
Explore other medications manufactured by Aurobindo Pharma Limited and compare their safety profiles:
The following drugs share commonly reported adverse reactions with Trelegy: